SEC Form	4
----------	---

П

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

1	OMB Number:	3235-0287
	Estimated average burc	len
	hours per response:	0.5

1. Name and Address of Reporting Feison			2. Issuer Name and Ticker or Trading Symbol <u>AMGEN INC</u> [AMGN]		ionship of Reporting Pers all applicable) Director	10% Owner	
(Last) ONE AMGEN	ast) (First) (Middle) NE AMGEN CENTER DRIVE		3. Date of Earliest Transaction (Month/Day/Year) 07/31/2012	- X	Officer (give title below) VP, Finance &	Other (specify below) CAO	
(Street) THOUSAND OAKS	СА	91320	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indivi Line) X	dual or Joint/Group Filing Form filed by One Repo Form filed by More thar Person	orting Person	
(City)	(State)	(Zip)					

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code (8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(1150.4)	
Common Stock	07/31/2012		М		25,000	A	\$69.83	38,721	D		
Common Stock	07/31/2012		М		3,000	A	\$42.13	41,721	D		
Common Stock	07/31/2012		М		2,000	A	\$50.44	43,721	D		
Common Stock	07/31/2012		М		2,150	A	\$58.43	45,871	D		
Common Stock	07/31/2012		S		32,150	D	\$82.687(1)	13,721 ⁽²⁾⁽³⁾	D		

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

(e.g., puts, cans, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		of Deri Seci Acq (A) o Disp of (E	umber vative urities uired or oosed o) (Instr. and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		e and 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Nqso (Right to Buy)	\$69.83	07/31/2012		М			25,000	05/15/2007	05/15/2013	Common Stock	25,000	\$0	0	D	
Nqso (Right to Buy)	\$42.13	07/31/2012		М			3,000	04/29/2009	04/29/2015	Common Stock	3,000	\$0	0	D	
Nqso (Right to Buy)	\$50.44	07/31/2012		М			2,000	04/28/2010	04/28/2016	Common Stock	2,000	\$0	2,000	D	
Nqso (Right to Buy)	\$58.43	07/31/2012		М			2,150	04/26/2011	04/26/2020	Common Stock	2,150	\$0	4,300	D	

Explanation of Responses:

1. The price reported is an average price. The prices ranged from \$82.67 to \$82.75 per share. Full information regarding the number of shares sold at each separate price within the range set forth above is available upon request by the SEC, the issuer or a security holder of the issuer.

2. The shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 286 RSUs which fully vest on 4/28/2013; 615 RSUs which vest in annual installments of 307 on 4/26/2013 and 308 on 4/26/2014; 1,714 RSUs which vest in annual installments of 565, 566 and 583 on 4/25/2013, 4/25/2014 and 4/25/2015, respectively; and 1,400 RSUs which vest in two equal installments of 476 on 4/27/2016. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

3. These shares include 7 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

<u>/s/ Thomas J.W. Dittrich</u> 07/31/2012

** Signature of Reporting Person Da

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.